← Back to Cancer ScreeningFDA approved
Shield by Guardant
Adults 45+ wanting non-invasive CRC screening
$895
Test Performance
Sensitivity
84% for CRC
Specificity
90%
Detection Method
ctDNA
Turnaround
10-14 days
Key Features
FDA-approved for CRC • Medicare coverage • Blood-based alternative to colonoscopy • Primary screening option
Who It's For
Important Notes
First FDA-approved blood test for primary CRC screening. Shield V2 algorithm. Available via Quest starting Q1 2026.
Learn more about Shield by Guardant
Discuss with your physician before ordering.
Visit Shield by GuardantCompare All